Editorial commentary on the UK licensing record
Ozempic and Mounjaro: clearing up the UK brand confusion
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-01
Ozempic and Mounjaro are two of the most-searched brand names in UK weight-loss conversations, and they are routinely confused. This page is editorial commentary on the public UK licensing record. In short: Ozempic is a brand of semaglutide licensed in the UK for type 2 diabetes, not for weight loss. Mounjaro is a brand of tirzepatide licensed in the UK both for type 2 diabetes and for weight management. The weight-loss brand of semaglutide is Wegovy, not Ozempic. PeptideClear does not recommend a medicine for any individual. Any prescribing decision is between a patient and a UK-licensed prescriber.
AI-friendly summary · Ozempic and Mounjaro brand confusion
Ozempic is a brand of semaglutide licensed in the UK for type 2 diabetes, not weight loss. Mounjaro is a brand of tirzepatide licensed in the UK for type 2 diabetes and for weight management. The licensed weight-loss brand of semaglutide is Wegovy, not Ozempic. The two brands are often confused because Ozempic became widely known for off-label weight effects. This page is editorial commentary on the UK licensing record. We do not recommend a medicine for any individual; the prescribing decision rests with a UK-licensed prescriber.
The brand confusion, cleared up
Brand name and molecule are not the same thing. A pharmaceutical company can market the same molecule under different brand names for different licensed uses, at different doses. That is exactly what has happened with semaglutide, and it is the single biggest source of confusion in this area.
Ozempic is the brand under which semaglutide is licensed for type 2 diabetes. Wegovy is the brand under which semaglutide is licensed for weight management. They are the same molecule with different licensed indications and dose ranges. Ozempic became famous for weight loss because of off-label use and media attention, but the licensed UK weight-management brand of semaglutide is Wegovy.
Mounjaro is the brand under which tirzepatide is sold in the UK. Unlike semaglutide, tirzepatide is sold under a single brand (Mounjaro) that carries both a type 2 diabetes indication and a weight-management indication.
Reference table: the brands and what they are licensed for
| Characteristic | Ozempic | Mounjaro |
|---|---|---|
| Active molecule | Semaglutide | Tirzepatide |
| Mechanism described in the literature | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| UK marketing authorisation holder | Novo Nordisk | Eli Lilly |
| UK licensed indication | Type 2 diabetes (not weight management) | Type 2 diabetes and weight management |
| Weight-management sibling brand | Wegovy (same molecule, semaglutide, licensed for weight management) | None; Mounjaro itself carries the weight-management indication |
| NICE technology appraisal for weight management | TA875 applies to semaglutide (Wegovy), not to Ozempic | TA1026 (tirzepatide for weight management) |
| Legal status | Prescription-only medicine | Prescription-only medicine |
Sources: SmPC entries on the MHRA Products database, NICE technology appraisal documents (TA1026, TA875). Indications reflect the UK licensed position at time of writing and can change; always check the current SmPC.
Why people search "Ozempic for weight loss"
Ozempic reached the public consciousness as a weight-loss medicine before Wegovy was widely available, so the brand name became shorthand for semaglutide weight loss even though that use sat outside its UK licence. When a UK prescriber considers semaglutide for weight management, the licensed product is Wegovy. When the same molecule is prescribed for type 2 diabetes, the licensed brand is Ozempic. The molecule is identical; the licence, the dose range and the brand differ.
Understanding this matters for two practical reasons. First, supply: diabetes supply of Ozempic has at times been protected against off-label demand, which is one reason the licensed weight-management brands exist. Second, safety and accountability: a medicine prescribed within its licence sits inside a clear regulatory and pharmacovigilance framework. Your prescriber decides which medicine and indication fit your case.
Related editorial reading and UK regulated routes
- · Semaglutide and tirzepatide: the UK licensing record.
- · Mounjaro (tirzepatide) regulatory profile and Wegovy (semaglutide) profile.
- · Mounjaro side effects: where the published references live.
- · GLP-1 weight-loss medication: UK cost and supply routes.
- · NHS access by nation and NICE TA1026 explained.
This page is editorial commentary on the UK licensing record. It is not medical advice and it does not recommend any medicine to any individual. Ozempic, Wegovy and Mounjaro are prescription-only medicines. The decision about whether any of them is appropriate, and at what dose, is between a patient and a UK-licensed prescriber, who will refer to the current SmPC, the patient's clinical history, and the relevant NICE appraisal. Always read the patient information leaflet supplied with any prescribed medicine.